Brief: Lepu Biopharma Enters Licensing Deal With Excalipoint
01/08/2025 11:37
Aug 1 (Reuters) - Lepu Biopharma Co Ltd 2157.HK: ENTERS LICENSING DEAL WITH EXCALIPOINT TO RECEIVE UP TO $847.5 MILLION IN MILESTONES UNDER DEAL TO RECEIVE UPFRONT $10 MILLION CASH AND 10% EQUITY, OTHERS Further company coverage: 2157.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lepu Biopharma
See all newsChina's Lepu Biopharma H1 revenue rises 12.1% on higher drug sales
Hong Kong-listed Keymed Biosciences' gastric cancer drug meets late-stage trial goals
Brief: Lepu Biopharma Reports Positive Top-Line Results From Global Phase III Trial Of CMG901 (AZD0901)
Lepu Biopharma set to jump most in 7 months on FY profit forecast
Brief: Lepu Biopharma Expects FY Net Profit Attributable